Performance of surgical site infection risk prediction models in colorectal surgery: external validity assessment from three European national surveillance networks.


Journal

Infection control and hospital epidemiology
ISSN: 1559-6834
Titre abrégé: Infect Control Hosp Epidemiol
Pays: United States
ID NLM: 8804099

Informations de publication

Date de publication:
09 2019
Historique:
pubmed: 21 6 2019
medline: 14 5 2020
entrez: 21 6 2019
Statut: ppublish

Résumé

To assess the validity of multivariable models for predicting risk of surgical site infection (SSI) after colorectal surgery based on routinely collected data in national surveillance networks. Retrospective analysis performed on 3 validation cohorts. Colorectal surgery patients in Switzerland, France, and England, 2007-2017. We determined calibration and discrimination (ie, area under the curve, AUC) of the COLA (contamination class, obesity, laparoscopy, American Society of Anesthesiologists [ASA]) multivariable risk model and the National Healthcare Safety Network (NHSN) multivariable risk model in each cohort. A new score was constructed based on multivariable analysis of the Swiss cohort following colorectal surgery, then based on colon and rectal surgery separately. We included 40,813 patients who had undergone elective or emergency colorectal surgery to validate the COLA score, 45,216 patients to validate the NHSN colon and rectal surgery risk models, and 46,320 patients in the construction of a new predictive model. The COLA score's predictive ability was poor, with AUC values of 0.64 (95% confidence interval [CI], 0.63-0.65), 0.62 (95% CI, 0.58-0.67), 0.60 (95% CI, 0.58-0.61) in the Swiss, French, and English cohorts, respectively. The NHSN colon-specific model (AUC, 0.61; 95% CI, 0.61-0.62) and the rectal surgery-specific model (AUC, 0.57; 95% CI, 0.53-0.61) showed limited predictive ability. The new predictive score showed poor predictive accuracy for colorectal surgery overall (AUC, 0.65; 95% CI, 0.64-0.66), for colon surgery (AUC, 0.65; 95% CI, 0.65-0.66), and for rectal surgery (AUC, 0.63; 95% CI, 0.60-0.66). Models based on routinely collected data in SSI surveillance networks poorly predict individual risk of SSI following colorectal surgery. Further models that include other more predictive variables could be developed and validated.

Identifiants

pubmed: 31218977
pii: S0899823X19001636
doi: 10.1017/ice.2019.163
doi:

Types de publication

Journal Article Multicenter Study Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

983-990

Auteurs

Rebecca Grant (R)

Infection Control Programme,University of Geneva Hospitals and Faculty of Medicine,Geneva,Switzerland.

Martine Aupee (M)

Coordination Center for Prevention and Control of Nosocomial Infections (CClin) Ouest,Rennes,France.

Nicolas C Buchs (NC)

Service of Visceral Surgery, Department of Surgery,University of Geneva Hospitals and Faculty of Medicine,Geneva,Switzerland.

Kristine Cooper (K)

National Infection Service,Public Health England, London,United Kingdom.

Marie-Christine Eisenring (MC)

Swissnoso,National Center for Infection Prevention,Bern,Switzerland.

Theresa Lamagni (T)

National Infection Service,Public Health England, London,United Kingdom.

Frédéric Ris (F)

Service of Visceral Surgery, Department of Surgery,University of Geneva Hospitals and Faculty of Medicine,Geneva,Switzerland.

Juliette Tanguy (J)

Coordination Center for Prevention and Control of Nosocomial Infections (CClin) Ouest,Rennes,France.

Nicolas Troillet (N)

Swissnoso,National Center for Infection Prevention,Bern,Switzerland.

Stephan Harbarth (S)

Infection Control Programme,University of Geneva Hospitals and Faculty of Medicine,Geneva,Switzerland.

Mohamed Abbas (M)

Infection Control Programme,University of Geneva Hospitals and Faculty of Medicine,Geneva,Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH